- Home
- TRNR vs HCWB Comparison
TRNR vs HCWB Comparison
Compare TRNR & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRNR | HCWB |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5M | 3.7M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TRNR | HCWB |
|---|---|---|
| Price | $1.58 | $0.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 13.3M | 79.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,380,000.00 | $4,099,750.00 |
| Revenue This Year | $245.67 | N/A |
| Revenue Next Year | $119.39 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 459.25 | N/A |
| 52 Week Low | $0.19 | $0.22 |
| 52 Week High | $8.20 | $17.80 |
Technical Indicators
Market Signals| Indicator | TRNR | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 61.89 | 24.86 |
| Support Level | $0.81 | N/A |
| Resistance Level | $1.62 | $1.35 |
| Average True Range (ATR) | 0.13 | 0.10 |
| MACD | 0.19 | -0.00 |
| Stochastic Oscillator | 60.11 | 10.08 |
Price Performance
Historical ComparisonAbout TRNR Interactive Strength Inc.
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue and personal training revenue.
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.